MTF Biologics, Kolosis BIO Introduce Two New Cardiac Allografts

MTF Biologics and Kolosis BIO (Kolosis) have partnered to commercialize two allograft tissues for cardiac surgeons: ATLAS Sternal Repair Matrix for sternal fusion and IKON Allograft Surgical Matrix for soft tissue repair in high-risk patients.

“The MTF Biologics team is pleased to apply our proven allografts, developed in collaboration with surgeons across the nation, to transform sternal fusion and wound healing in the cardiac space,” said Brad Bailey, vice president and general manager of MTF Biologics’ Orthopedic Franchise. “ATLAS and IKON will support clinicians caring for patients with complex challenges who are undergoing high-risk cardiac procedures. The Kolosis BIO team is an ideal partner to bring these solutions to this market with us.”

ATLAS Sternal Repair Matrix is a demineralized cortical bone allograft that is inserted between sternal edges prior to closure to support stabilization and fusion in challenging patient cases. Processed to preserve native growth factors and tested for osteoinductive potential, ATLAS offers an osteoconductive scaffold, rapid hydration, and proven bone-forming capacity.

IKON Allograft Surgical Matrix is applied within subcutaneous tissue after a sternal closure to support incision closure. IKON processing preserves growth factors and matrix proteins with a cell-friendly collagen structure to support wound closure in high-risk patients.

“For Kolosis, launching ATLAS and IKON in cardiac surgery is an exciting step into a new market, furthering our position as the premier pure-play biologics provider,” Kolosis BIO CEO Collin Begley stated. “These advanced allografts redefine standards for sternal repair and soft tissue repair, offering surgeons powerful new tools to improve outcomes.”

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. It provides service, resources, and expertise to organ and tissue donors and recipients, as well as healthcare providers, clinicians, and scientists. 

The International Institute for the Advancement of Medicine (IIAM), a division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients worldwide.  

Kolosis BIO is a biologics pure-play, dedicated to commercializing technologies to multiple verticals in the surgical biologics space. Kolosis is dedicated to driving innovation and pushing the boundaries of science to enhance patient outcomes. With a focus on providing bold technologies and execution, Kolosis has become a competitive force in the surgical biologics market.